DMDTP and the Dimethyl Organophosphate Family: Sources and How It's Measured

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

The dimethyldithiophosphate (DMDTP) test measures a urinary biomarker of recent exposure to dimethyl organophosphate pesticides. Identifying and reducing exposure may help you avoid acute symptoms (headaches, nausea) and lower the risk of longer-term nervous system and neurodevelopmental effects linked to these pesticides.

Read more →

Understand what your environmental toxins results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

DMDTP and the dimethyl organophosphate family

DMDTP is a urinary breakdown product of a group of insecticides called organophosphates. Specifically, it reflects exposure to dimethyl organophosphates used in agricultural pest control. People encounter these chemicals through food residues, air or dust near treated areas, and skin contact during mixing, loading, or application. Most labs measure DMDTP in urine using sensitive mass spectrometry, often alongside related metabolites (DMP, DMTP). Because organophosphates are rapidly processed and cleared, a DMDTP result represents recent exposure, typically over the past 1–3 days, rather than a long-term body burden.

Why DMDTP earns its place on a panel

Why it matters: organophosphates act on the nervous system by inhibiting acetylcholinesterase, an enzyme that helps turn off nerve signaling. At high exposure, this causes classic poisoning symptoms; at lower levels, research focuses on subtler effects on neurobehavior, endocrine signaling, oxidative stress, and mitochondrial function. The body absorbs organophosphates through the gut, lungs, and skin, converts them in the liver, and excretes the dialkyl phosphate metabolites in urine. These compounds are not persistent like older organochlorine pesticides, but repeated low-level contact can keep metabolite levels elevated, which is why targeted testing can be informative.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Who tends to benefit from DMDTP testing

Testing DMDTP connects what’s happening in your environment to how your body is handling it. Organophosphate exposures are often intermittent — a grocery run with lots of fresh produce, a weekend near fields during spray season, or a day helping in a garden with certain pest controls. A measured DMDTP level can help distinguish incidental contact from sustained exposure. That distinction matters when you’re troubleshooting nonspecific issues like frequent headaches, brain fog, sleep disruption, or gut cramping, especially if your work or home setting raises the odds of contact. It’s also useful when life stage magnifies stakes: pregnancy, fertility planning, early childhood, or chronic neurologic conditions where added system stress is unhelpful. Population biomonitoring studies have used urinary organophosphate metabolites for exactly this purpose — to map what’s typical and identify outliers, then look for patterns over time.

Reading a DMDTP result

Labs typically report DMDTP against reference values derived from large population samples. Because DMDTP is a marker of exposure rather than a nutrient, values toward the lower end are generally preferable when achievable. A clinician's interpretation is strongest when you know what happened in the few days before your test — meals, locations, and tasks — and when you repeat testing to confirm a pattern. Many labs also provide creatinine-corrected values to account for hydration, since dilute urine can make levels look artificially low and concentrated urine can make them look higher.

Relatively low values usually indicate limited recent exposure and a lower likelihood of short-term system stress from dimethyl organophosphates. For most healthy adults, that suggests the nervous system and detox pathways are not dealing with a meaningful current load. In pregnancy and early childhood, where developing brains are especially sensitive to neuroactive chemicals, lower exposure markers are generally considered reassuring, though results always need clinical context.

Relatively higher values can signal recent or ongoing contact with dimethyl organophosphate pesticides. That can place extra work on metabolic and clearance pathways in the liver and kidneys and, depending on magnitude and frequency, may nudge neural signaling toward imbalance through acetylcholinesterase inhibition. Some people notice nonspecific symptoms in these windows — headaches, dizziness, irritability, or abdominal cramping — while others feel nothing at all. Because urinary metabolites clear quickly, a single higher value is best confirmed with trend testing and paired with what you know about your exposures. One important caveat: foods can contain “preformed” dialkyl phosphates that are less toxic than the parent pesticides but still show up in urine; this can inflate results without indicating the same biological impact, which is why patterns and context matter.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What to interpret DMDTP alongside

Big picture, your environmental toxin results are one piece of the health puzzle. DMDTP trends make the most sense alongside related biomarkers (other organophosphate metabolites, general liver and kidney function markers) and what you know about your week-to-week routines. For example, a one-time bump may simply reflect a recent exposure window, while a persistently higher pattern suggests ongoing contact that merits a closer look. Epidemiologic research links higher prenatal organophosphate biomarker levels with small differences in child attention and cognition, though findings vary and more research is needed. That’s why context and repetition matter more than any single datapoint.

What a DMDTP test can and can't tell you

Ultimately, a DMDTP result is most powerful when combined with other signals: related organophosphate metabolites, general health markers, and your lived environment. Over weeks to months, that combination helps separate transient spikes from persistent exposure and supports smarter, safer choices in partnership with your clinician. Think of it like the way athletes look at workout recovery — not just one heart rate reading, but trends, sleep, and how they actually feel. With DMDTP, the aim is similar: use clear, current data to make level-headed decisions, especially during sensitive life stages or in higher-exposure settings. As with all environmental health testing, results are informative rather than diagnostic, and they’re most actionable when they’re part of a broader, thoughtful plan.

Frequently Asked Questions

References

  1. Costa LG (2006). Current issues in organophosphate toxicology. *Clinica Chimica Acta*, *366*(1-2), 1-13. https://doi.org/10.1016/j.cca.2005.10.008
  2. Barr DB, Wong LY, Bravo R, Weerasekera G, Odetokun M, Restrepo P, Kim DG, Fernandez C, Whitehead RD, Perez J, Gallegos M, Williams BL, Needham LL (2011). Urinary concentrations of dialkylphosphate metabolites of organophosphorus pesticides: National Health and Nutrition Examination Survey 1999-2004. *International Journal of Environmental Research and Public Health*, *8*(8), 3063-3098. https://doi.org/10.3390/ijerph8083063
  3. Chen L, Zhao T, Pan C, Ross JH, Krieger RI (2012). Preformed biomarkers including dialkylphosphates (DAPs) in produce may confound biomonitoring in pesticide exposure and risk assessment. *Journal of Agricultural and Food Chemistry*, *60*(36), 9342-9351. https://doi.org/10.1021/jf303116p
  4. Bouchard MF, Chevrier J, Harley KG, Kogut K, Vedar M, Calderon N, Trujillo C, Johnson C, Bradman A, Barr DB, Eskenazi B (2011). Prenatal exposure to organophosphate pesticides and IQ in 7-year-old children. *Environmental Health Perspectives*, *119*(8), 1189-1195. https://doi.org/10.1289/ehp.1003185
  5. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL (2005). Urinary creatinine concentrations in the U.S. population: Implications for urinary biologic monitoring measurements. *Environmental Health Perspectives*, *113*(2), 192-200. https://doi.org/10.1289/ehp.7337

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey